Coronary heart disease in China

Area of Science:

• Cardiology
• Public Health
• Epidemiology

Background:

• Coronary heart disease (CHD) is the second leading cause of cardiovascular death in China, with significant prevalence in both urban and rural areas.
• Despite lower mortality rates compared to Western countries, the overall burden of CHD is rising due to an aging population and increased prevalence of risk factors like hypertension, hyperlipidemia, obesity, and diabetes.

Purpose of the Study:

• To review and synthesize findings from large-scale, randomized controlled trials (RCTs) relevant to the Chinese population with myocardial infarction.
• To provide evidence-based information for the prevention and management of both chronic CHD and acute myocardial infarction within China.

Main Methods:

• Review of large-scale, randomized controlled trials (RCTs).
• Focus on treatments including thrombolytic therapy, blood-pressure-lowering agents, antiplatelet drugs, blood-cholesterol-lowering treatments, and cardiac interventions.
• Analysis of data pertaining to Chinese patients diagnosed with myocardial infarction.

Main Results:

• Multiple RCTs have been conducted for Chinese patients with myocardial infarction, evaluating various therapeutic strategies.
• The studies encompass a range of interventions crucial for cardiovascular disease management.
• Evidence generated from these trials is pertinent to the specific context of the Chinese healthcare system and patient population.

Conclusions:

• The conducted studies offer critical data for the effective prevention and management of chronic CHD in China.
• Findings are essential for optimizing the treatment strategies for acute myocardial infarction among Chinese patients.
• This body of research supports evidence-based clinical practice for cardiovascular disease in China.